News

Amgen is dealing with the threat of several fast-approaching patent expirations. The drugmaker's dividend streak is ...
Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy. On June 24, Piper Sandler reaffirmed its ...
Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.
On June 24, Piper Sandler reaffirmed its Overweight rating and $328 price target for Amgen Inc. (NASDAQ:AMGN) in response to the company’s disclosure of comprehensive MariTide tolerability data.
Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations.
MariTide, a new drug from Amgen, helped some people with obesity lose up to 20% of their body weight. In a phase 2 trial, a new GLP-1 drug helped people lose up to 20% of their body weight over a year ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Viking Therapeutics's obesity/diabetes candidates and strong financials position it for success. Read here for an investment ...
Amgen still needs to show that the reduction in Lp (a) is accompanied by lower rates of cardiovascular outcomes, and will endeavour to show that in its phase 3 programme which will start to enrol ...